Sodium-glucose co-transporter 2 (SGLT2) inhibitors have emerged as a novel class of drugs in heart failure management, originally developed for glycemic control in type 2 diabetes. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.